ProCE Banner Activity

We Can and Should Do Better With Identification and Treatment of Postpartum Depression

Clinical Thought

Maternal mortality is rising in the United States and is increasingly driven by mental health conditions, particularly postpartum depression (PPD). Despite PPD’s significant impact on both mothers and their newborns, less than half of all cases are identified and treated. Learn about screening and treatment of PPD including the role of newly approved GABAergic agents.

Released: August 26, 2024

Expiration: August 25, 2025

Share

Faculty

Jennifer L Payne

Jennifer L Payne, MD

Professor and Vice Chair of Research
Department of Psychiatry and Neurobehavioral Sciences
University of Virginia
Charlottesville, Virginia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Sage Therapeutics, Inc. and Biogen.

Biogen

Sage Therapeutics, Inc.

Disclosure

Primary Author

Jennifer L Payne, MD

Professor and Vice Chair of Research
Department of Psychiatry and Neurobehavioral Sciences
University of Virginia
Charlottesville, Virginia

Jennifer L. Payne, MD: consultant/advisor/speaker: Biogen, Brii Biosciences, Sage Therapeutics; researcher: Janssen, Myriad.